339 related articles for article (PubMed ID: 18717215)
1. Hypertrophic cardiomyopathy--state of the art in 2007.
Monteiro S; Costa S; Monteiro P; Gonçalves L; Providência LA
Rev Port Cardiol; 2008 May; 27(5):625-37. PubMed ID: 18717215
[TBL] [Abstract][Full Text] [Related]
2. Sudden death and hypertrophic cardiomyopathy: a review.
Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
[TBL] [Abstract][Full Text] [Related]
3. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy.
Miller MA; Gomes JA; Fuster V
Nat Clin Pract Cardiovasc Med; 2007 Dec; 4(12):667-76. PubMed ID: 18033231
[TBL] [Abstract][Full Text] [Related]
4. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
[TBL] [Abstract][Full Text] [Related]
5. Malignant mutations in hypertrophic cardiomyopathy: fact or fancy?
Brito D; Madeira H
Rev Port Cardiol; 2005 Sep; 24(9):1137-46. PubMed ID: 16335287
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
[TBL] [Abstract][Full Text] [Related]
7. Genetic basis of hypertrophic cardiomyopathy.
Lind JM; Chiu C; Semsarian C
Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):927-34. PubMed ID: 17173506
[TBL] [Abstract][Full Text] [Related]
8. The pathology of hypertrophic cardiomyopathy.
Hughes SE
Histopathology; 2004 May; 44(5):412-27. PubMed ID: 15139989
[TBL] [Abstract][Full Text] [Related]
9. Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy.
Mogensen J; Murphy RT; Kubo T; Bahl A; Moon JC; Klausen IC; Elliott PM; McKenna WJ
J Am Coll Cardiol; 2004 Dec; 44(12):2315-25. PubMed ID: 15607392
[TBL] [Abstract][Full Text] [Related]
10. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
11. Advances in the prevention of sudden cardiac death in the young.
Shephard R; Semsarian C
Ther Adv Cardiovasc Dis; 2009 Apr; 3(2):145-55. PubMed ID: 19144665
[TBL] [Abstract][Full Text] [Related]
12. [Therapy and risk-stratification in hypertrophic cardiomyopathy--a current survey].
Reith S; Klues HG
Z Kardiol; 2003 Apr; 92(4):283-93. PubMed ID: 12707787
[TBL] [Abstract][Full Text] [Related]
13. [Use of an implantable defibrillator for the prevention of sudden death in hypertrophic cardiomyopathy].
Hentati M; Ben Ameur I; Kechida Z; Charfeddine H; Hached L; Grati Z; Kammoun S
Tunis Med; 2003; 81 Suppl 8():675-9. PubMed ID: 14608758
[TBL] [Abstract][Full Text] [Related]
14. Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene.
Cardim N; Perrot A; Santos S; Morgado P; Pádua M; Ferreira S; Reis RP; Monteiro C; Ferreira T; Correia JM; Osterziel KJ
Rev Port Cardiol; 2005 Dec; 24(12):1463-76. PubMed ID: 16566405
[TBL] [Abstract][Full Text] [Related]
15. Syncope, other risk factors, and the implantable defibrillator for sudden death prevention in hypertrophic cardiomyopathy.
Cotiga D; Ehlert F; Sherrid M
Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():55-60. PubMed ID: 17162272
[TBL] [Abstract][Full Text] [Related]
16. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P
J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1118-26. PubMed ID: 18384577
[TBL] [Abstract][Full Text] [Related]
17. Hypertrophic cardiomyopathy and sudden death: new perspectives on risk stratification and prevention with the implantable cardioverter-defibrillator.
Maron BJ
Eur Heart J; 2000 Dec; 21(24):1979-83. PubMed ID: 11102243
[No Abstract] [Full Text] [Related]
18. Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy.
Kabaeva ZT; Perrot A; Wolter B; Dietz R; Cardim N; Correia JM; Schulte HD; Aldashev AA; Mirrakhimov MM; Osterziel KJ
Eur J Hum Genet; 2002 Nov; 10(11):741-8. PubMed ID: 12404107
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.
Decker JA; Rossano JW; Smith EO; Cannon B; Clunie SK; Gates C; Jefferies JL; Kim JJ; Price JF; Dreyer WJ; Towbin JA; Denfield SW
J Am Coll Cardiol; 2009 Jul; 54(3):250-4. PubMed ID: 19589438
[TBL] [Abstract][Full Text] [Related]
20. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Vriesendorp PA; Schinkel AF; Liebregts M; Theuns DA; van Cleemput J; Ten Cate FJ; Willems R; Michels M
Circ Arrhythm Electrophysiol; 2015 Aug; 8(4):829-35. PubMed ID: 25922410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
